Cognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment

Cognition Therapeutics (CGTX) announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium, ACTC, with $81 million in grant support from the National Institute of Aging, NIA, at the National Institutes of Health. Christopher van Dyck, MD, stated, “This is an important milestone for the study and is a testament to the commitment of the investigators and site teams and a high level of interest from participants in an oral treatment with a novel approach to addressing amyloid in early Alzheimer’s disease.” Dr. Van Dyck is the director of the Yale Alzheimer’s Disease Research Unit and the Yale Alzheimer’s Disease Research Center. He also serves as a member of the ACTC executive committee and is the project director of the START Study.